Synapse - Tiffany Troso-Sandoval

Results (49)

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study

Journal Article

Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
Breast Cancer Research and Treatment (2022)

Fulltext@MSK | Save

Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: An open-label, four-arm, phase II study

Journal Article

Moore, K. N.; Chambers, S. K.; Hamilton, E. P.; Chen, L. M.; Oza, A. M.; Ghamande, S. A.; Konecny, G. E.; Plaxe, S. C.; Spitz, D. L.; Geenen, J. J. J.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Meeting Abstract

Lumish, M. A.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z. K.; Ku, G. Y.; Segal, N. H.; Won, E.; Maron, S. B.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study

Journal Article

Zivanovic, O.; Chi, D. S.; Zhou, Q.; Iasonos, A.; Konner, J. A.; Makker, V.; Grisham, R. N.; Brown, A. K.; Nerenstone, S.; Diaz, J. P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Meeting Abstract

Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR plus ) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC)

Meeting Abstract

Grisham, R. N.; Li, K.; Iasonos, A.; Girshman, J.; Cadoo, K. A.; Kyi, C.; Makker, V.; Cohen, S. M.; O'Cearbhaill, R. E.; Sabbatini, P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial

Journal Article

Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J. F.; Troso-Sandoval, T. A.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R.; Chan, A.; more...
Lancet Oncology (2020)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer

Meeting Abstract

Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J. F.; Troso-Sandoval, T. A.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R. D.; Chan, A.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

Journal Article

Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
Cancer (2020)

Fulltext@MSK | Save

A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer

Meeting Abstract

Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save